First Patient Dosed with Gadeta’s gamma delta TCR Cell Therapy

GDT-002 is a potential first-in-class cellular immunotherapy

UTRECHT, Netherlands and BOSTONJuly 6, 2021 /PRNewswire/ — Gadeta B.V., a clinical-stage company developing innovative, gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for cancer patients, today announced the dosing of the first patient with GDT-002 (formerly labelled TEG002), a potential first-in-class cellular immunotherapy for the treatment of cancer.

The multicenter phase 1/2 study in collaboration with the Dana-Farber Cancer Institute, Mass General Brigham Cancer Care and Beth Israel Deaconess Medical Center, is evaluating safety, tolerability and preliminary efficacy of GDT-002 for the treatment of multiple myeloma (MM).

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...